---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-26-000058"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:47:17.839219+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Exelixis Q1 revenue $610.8M, GAAP EPS $0.79; announces $750M buyback

## Summary
- Total revenues $610.8M (+10% YoY); cabozantinib U.S. net product revenue $555.0M.
- GAAP diluted EPS $0.79 (vs. $0.55 in Q1 2025); non-GAAP diluted EPS $0.87.
- Board authorized new $750M stock repurchase program through Dec 31, 2027.
- Zanzalintinib NDA accepted for colorectal cancer; PDUFA target Dec 3, 2026.
- Company plans to complete current $750M buyback this month.

## SEC filing metadata
- accession: 0000939767-26-000058
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/0000939767-26-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-26-000058
- JSON: https://secwatch.observer/filing/0000939767-26-000058.json
- Plain text: https://secwatch.observer/filing/0000939767-26-000058.txt

## Key facts
- Earnings Releases
  EXELIXIS, INC. reported first quarter of 2026 results: revenue $610.8 million, net income $210.5 million, EPS $0.79 per share, diluted.
  - Period: first quarter of 2026
  - Revenue: $610.8 million
  - Net income: $210.5 million
  - EPS: $0.79 per share, diluted
  - Result: reported results
  source text: & Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/0000939767-26-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.